Transition Theory of An Electron Traveling from Uncertain to Causal Basis
Fuente:
Zenodo
Guardado en:
| Autor principal: | Hanamura, Satoshi |
|---|---|
| Formato: | Recurso digital |
| Lenguaje: | inglés |
| Publicado: |
Zenodo
2019
|
| Materias: | |
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
Beyond the Standard Model: Neutrino Oscillations and the Search for New Physics
por: Hanamura, Satoshi
Publicado: (2023)
por: Hanamura, Satoshi
Publicado: (2023)
Liver iron concentration thresholds: Where do they really come from?
por: Lukas Müller, et al.
Publicado: (2025)
por: Lukas Müller, et al.
Publicado: (2025)
Exciting science from the 16th International Conference on Thalassemia and Hemoglobinopathies
por: Dimitrios Farmakis, et al.
Publicado: (2024)
por: Dimitrios Farmakis, et al.
Publicado: (2024)
Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium
por: Cristina A. Tentori, et al.
Publicado: (2024)
por: Cristina A. Tentori, et al.
Publicado: (2024)
Lower efficacy of transfusion of red blood cells from donors with sickle cell trait
por: Monika Dzieciatkowska, et al.
Publicado: (2026)
por: Monika Dzieciatkowska, et al.
Publicado: (2026)
Caplacizumab treatment in elderly patients with iTTP: Experience from the Spanish TTP Registry
por: Inés Gómez‐Seguí, et al.
Publicado: (2025)
por: Inés Gómez‐Seguí, et al.
Publicado: (2025)
Testicular large B‐cell lymphoma is genetically similar to PCNSL and distinct from nodal DLBCL
por: Alfredo Rivas‐Delgado, et al.
Publicado: (2024)
por: Alfredo Rivas‐Delgado, et al.
Publicado: (2024)
Kinetics of hematologic response in AL amyloidosis: Insights from clinical and cytogenetic subgroup analysis in the daratumumab era
por: Abdul‐Hamid Bazarbachi, et al.
Publicado: (2025)
por: Abdul‐Hamid Bazarbachi, et al.
Publicado: (2025)
Hematology in times of crisis: Lessons learned and strategic priorities from the EHA–ASH Joint Workshop on Ukraine
por: Oleksandr Istomin, et al.
Publicado: (2026)
por: Oleksandr Istomin, et al.
Publicado: (2026)
Pharmacological inhibition of sclerostin protects bone from B‐cell acute lymphoblastic leukemia‐mediated destruction
por: Vincent Kuek, et al.
Publicado: (2026)
por: Vincent Kuek, et al.
Publicado: (2026)
Who owns that blood? Recontacting donors with results from genetic testing after allogeneic hematopoietic cell transplantation
por: Mirjam E. Belderbos, et al.
Publicado: (2025)
por: Mirjam E. Belderbos, et al.
Publicado: (2025)
Results from UKALL60+, a phase 2 study in older patients with untreated acute lymphoblastic leukemia
por: Bela Patel, et al.
Publicado: (2024)
por: Bela Patel, et al.
Publicado: (2024)
Prognostic risk and survival of asymptomatic IgM monoclonal gammopathy: Results from a Spanish Multicenter Registry
por: David F. Moreno, et al.
Publicado: (2024)
por: David F. Moreno, et al.
Publicado: (2024)
Clonal hematopoiesis dynamics influences long‐term outcomes of follicular lymphoma: Results from FIL FOLL12 trial
por: Nawar Maher, et al.
Publicado: (2026)
por: Nawar Maher, et al.
Publicado: (2026)
Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study
por: Sonia Morè, et al.
Publicado: (2025)
por: Sonia Morè, et al.
Publicado: (2025)
Efficacy of anti‐PD1 therapy in extranodal NK/T cell lymphoma: A matched cohort analysis from the LYSA
por: Amira Marouf, et al.
Publicado: (2025)
por: Amira Marouf, et al.
Publicado: (2025)
Elevated serum heme oxygenase‐1 in pediatric sickle cell disease: Insights from the SickleGenAfrica Network
por: Anna M. Sowa, et al.
Publicado: (2025)
por: Anna M. Sowa, et al.
Publicado: (2025)
Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network
por: Niels W. C. J. van de Donk, et al.
Publicado: (2025)
por: Niels W. C. J. van de Donk, et al.
Publicado: (2025)
Daratumumab‐based quadruplet for patients with extramedullary multiple myeloma: Results from the Phase II prospective EMN19 study
por: Meral Beksac, et al.
Publicado: (2026)
por: Meral Beksac, et al.
Publicado: (2026)
Cumulative review of cardiac failure with acalabrutinib in the treatment of chronic lymphocytic leukemia using data from clinical trials and postmarketing experience
por: Paolo Ghia, et al.
Publicado: (2025)
por: Paolo Ghia, et al.
Publicado: (2025)
Early progression beyond first‐line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study
por: Alberto Bavieri, et al.
Publicado: (2024)
por: Alberto Bavieri, et al.
Publicado: (2024)
Long‐term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: Update from the MagnetisMM‐3 study
por: Michael H. Tomasson, et al.
Publicado: (2024)
por: Michael H. Tomasson, et al.
Publicado: (2024)
Mitochondrial retention in mature red blood cells from patients with sickle cell disease is associated with stress erythropoiesis but not with proinflammatory state
por: Marc Romana, et al.
Publicado: (2024)
por: Marc Romana, et al.
Publicado: (2024)
Mitigation of atrial fibrillation‐related complications with antithrombotic and cytoreductive therapy in patients with Myeloproliferative Neoplasms: Implications from the GSG‐MPN bioregistry
por: Hyunyee Rosa Cho, et al.
Publicado: (2025)
por: Hyunyee Rosa Cho, et al.
Publicado: (2025)
Correction to Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study
Publicado: (2025)
Publicado: (2025)
How to diagnose acid sphingomyelinase deficiency (ASMD) and Niemann–Pick disease type C from bone marrow and peripheral blood smears
por: Sandrine Girard, et al.
Publicado: (2024)
por: Sandrine Girard, et al.
Publicado: (2024)
The role of time to first progression and fitness status in elderly patients with mantle cell lymphoma: Results from the ELDERLY MANTLE‐FIRST study
por: Francesca Maria Quaglia, et al.
Publicado: (2025)
por: Francesca Maria Quaglia, et al.
Publicado: (2025)
Patient and physician perceptions regarding treatment expectations and symptomatology in polycythemia vera: Insights from the Landmark 2.0 global health survey
por: Claire N. Harrison, et al.
Publicado: (2025)
por: Claire N. Harrison, et al.
Publicado: (2025)
The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study
por: Andrew D. Zelenetz, et al.
Publicado: (2024)
por: Andrew D. Zelenetz, et al.
Publicado: (2024)
Serum TARC dynamics during anti‐PD1‐based first‐line Hodgkin lymphoma treatment: An analysis from the GHSG NIVAHL trial
por: Wouter J. Plattel, et al.
Publicado: (2025)
por: Wouter J. Plattel, et al.
Publicado: (2025)
The role of trephine bone marrow biopsies in the era of measurable residual disease — Results from the CLL10 trial of the German CLL Study Group (GCLLSG)
por: Nadine Kutsch, et al.
Publicado: (2024)
por: Nadine Kutsch, et al.
Publicado: (2024)
Operational burden and fragmented implementation in CAR T‐cell therapy: Insights from a multinational survey by the GoCART Coalition and the JACIE Quality Managers Committee
por: Nick van Sinderen, et al.
Publicado: (2025)
por: Nick van Sinderen, et al.
Publicado: (2025)
Outcomes and salvage strategies for large B‐cell lymphoma progressing after second‐line CAR T‐cell therapy: A DESCAR‐T study from the LYSA group
por: Pierre Sesques, et al.
Publicado: (2026)
por: Pierre Sesques, et al.
Publicado: (2026)
Extracellular vesicles from chronic lymphocytic leukemia cells promote leukemia aggressiveness by inducing the differentiation of monocytes into nurse‐like cells via an RNA‐dependent mechanism
por: Nathan Dubois, et al.
Publicado: (2025)
por: Nathan Dubois, et al.
Publicado: (2025)
Dissecting minimal residual disease dynamics to improve outcome prediction in mantle cell lymphoma: Data from the Fondazione Italiana Linfomi (FIL)‐MCL0208 clinical trial
por: Francesca Cordero, et al.
Publicado: (2026)
por: Francesca Cordero, et al.
Publicado: (2026)
Clinical impact of immunoglobulin heavy chain repertoire in mantle cell lymphoma: A study from the Fondazione Italiana Linfomi (FIL) Phase III MCL0208 trial
por: Simone Ragaini, et al.
Publicado: (2026)
por: Simone Ragaini, et al.
Publicado: (2026)
Improved post‐transplant outcomes since 2000 for Ph‐positive acute lymphoblastic leukemia in first remission: A study from the EBMT Acute Leukemia Working Party
por: Ali Bazarbachi, et al.
Publicado: (2025)
por: Ali Bazarbachi, et al.
Publicado: (2025)
CHIC: A machine learning framework for inferring the presence of high‐risk clonal hematopoiesis using complete blood count data from 431,531 UK Biobank participants
por: William G. Dunn, et al.
Publicado: (2025)
por: William G. Dunn, et al.
Publicado: (2025)
Outcomes of patients with relapsed or refractory primary mediastinal B‐cell lymphoma treated with anti‐CD19 CAR‐T cells: CARTHYM, a study from the French national DESCAR‐T registry
por: Jean Galtier, et al.
Publicado: (2025)
por: Jean Galtier, et al.
Publicado: (2025)
Toward a more patient‐centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)
por: Fabio Efficace, et al.
Publicado: (2024)
por: Fabio Efficace, et al.
Publicado: (2024)
Ejemplares similares
-
Beyond the Standard Model: Neutrino Oscillations and the Search for New Physics
por: Hanamura, Satoshi
Publicado: (2023) -
Liver iron concentration thresholds: Where do they really come from?
por: Lukas Müller, et al.
Publicado: (2025) -
Exciting science from the 16th International Conference on Thalassemia and Hemoglobinopathies
por: Dimitrios Farmakis, et al.
Publicado: (2024) -
Immune‐monitoring of myelodysplastic neoplasms: Recommendations from the i4MDS consortium
por: Cristina A. Tentori, et al.
Publicado: (2024) -
Lower efficacy of transfusion of red blood cells from donors with sickle cell trait
por: Monika Dzieciatkowska, et al.
Publicado: (2026)